Acrotech Biopharma, LLC., and its wholly-owned subsidiary Allos Therapeutics, Inc.

Relentless commitment to oncology

A biopharmaceutical company committed to the development and commercialization of innovative anti-cancerCancer
A term for a group of diseases in which abnormal cells divide without control and can invade nearby tissues.

  • The focus: Oncology
  • Began operations: 2018
  • Obtained worldwide rights to first product candidate, pralatrexate: 2002
  • Acquired by Acrotech Biopharma, LLC. in 2019
  • Headquarters: East Windsor, NJ
  • The future

    Acrotech Biopharma, LLC. is committed to addressing a variety of cancers, especially in areas of high unmet need where there are few or no current treatment options.

    For more information, visit

Visit Spectrum Therapy Access Resources Web Site Patient Resources